AI Drug Discovery Startup Boltz Raises $110M Series A to Accelerate Small Molecule Research
Boltz PBC closed a $110M Series A led by Bessemer to scale its AI models that drastically reduce the workload for identifying promising small molecule drug candidates.
US-based AI drug discovery startup Boltz PBC announced it has raised $110 million in a Series A funding round. The round was led by Bessemer Venture Partners, with participation from Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital, Hummingbird, and others. According to SiliconANGLE, the new capital will be used to grow headcount and procure more computing infrastructure to support its AI models in pharmaceutical research.
Boltz's core product is an AI model called BoltzMol-1, designed to speed up early-stage small molecule screening. Traditionally, researchers must evaluate hundreds of thousands of candidate molecules to find "small molecule hits" with high binding affinity to pathogens, a process that can take months and cost millions. Boltz states that BoltzMol-1 generates binding affinity data by reviewing only a few dozen particularly promising molecules, significantly reducing analysis time. The company also offers BoltzProt-1, which generates tens of thousands of protein designs based on small molecule hit data and automatically evaluates their potential as drugs.
According to company reports, customer token consumption has grown by a factor of 50 since the models launched in June, and Boltz counts six of the world's top 20 pharmaceutical companies as clients. While specific valuation terms were not disclosed, this financing reflects continued investor confidence in AI's potential to lower costs and accelerate scientific discovery in the early stages of drug development.